Search

Displaying results 3971 - 3980 of 6198 in total
  1. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  2. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.

  3. Drug

    (R)-warfarin

    go.drugbank.com/drugs/DB08496
    Experimental

    Warfarin consists of a racemic mixture of two active enantiomers—R- and S- forms—each of which is cleared by different pathways. … S-warfarin is 2-5 times more potent than the R-isomer in producing an anticoagulant response.[A1038]

    Categories: Vitamin K Antagonists
  4. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    SB-269970 is an experimental drug developed by GlaxoSmithKline.

  5. Drug

    3-Allylfentanyl

    go.drugbank.com/drugs/DB09169
    ExperimentalIllicit

    3-allyfentanyl is a fentanyl derivative opioid that can cause itching, nausea and serious respiratory depression.

  6. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    Dihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity.

  7. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    It is also effective as an antineoplastic agent.

  8. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-

  9. Drug

    Brivaracetam

    go.drugbank.com/drugs/DB05541
    ApprovedInvestigational

    It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].

  10. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.